Approval · Notice of Compliance 23656 · 2020
ENVARSUS PA: Notice of Compliance 23656
Issued May 21, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23656
- Date
- May 21, 2020
- Company
- Endo Ventures Ltd
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To add information regarding a drug-drug interaction with letermovir to the Product Monograph.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENVARSUS PA | Not yet assigned | — |
Medicinal ingredients
- TACROLIMUS 0.75 MG per TAB
- TACROLIMUS 1 MG per TAB
- TACROLIMUS 4 MG per TAB